DKB 19002
Alternative Names: DKB-19002Latest Information Update: 28 Jan 2025
At a glance
- Originator DongKoo Bio&Pharma
 - Class Antihyperglycaemics
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- No development reported Diabetes mellitus
 
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Diabetes-mellitus in South Korea
 - 15 Dec 2021 Phase-I clinical trials in Diabetes mellitus in South Korea (unspecified route) in December 2021 (DongKoo Bio&Pharma pipeline; December 2021)
 - 06 May 2020 KFDA approves IND application for DKB 19002 in Diabetes mellitus in May 2020